These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 23159463)

  • 1. Genetic sequence variants are associated with severity of lower urinary tract symptoms and prostate cancer susceptibility.
    Helfand BT; Hu Q; Loeb S; McVary KT; Catalona WJ
    J Urol; 2013 Mar; 189(3):845-8. PubMed ID: 23159463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems.
    Parsons JK
    J Urol; 2007 Aug; 178(2):395-401. PubMed ID: 17561143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
    Huang SP; Huang LC; Ting WC; Chen LM; Chang TY; Lu TL; Lan YH; Liu CC; Yang WH; Lee HZ; Hsieh CJ; Bao BY
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3068-74. PubMed ID: 19900942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.
    Fukuta F; Masumori N; Mori M; Tsukamoto T
    Int J Urol; 2013 Jan; 20(1):100-6. PubMed ID: 23106204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can noninvasive evaluation of benign prostatic obstruction be optimized?
    Løvvik A; Yaqub S; Oustad H; Sand TE; Nitti VW
    Curr Opin Urol; 2012 Jan; 22(1):1-6. PubMed ID: 22080874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer.
    Sierra Díaz E; Sánchez Corona J; Rosales Gómez RC; Gutierrez Rubio SA; Vázquez Camacho JG; Solano Moreno H; Morán Moguel MC
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):241-6. PubMed ID: 20026870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men.
    Corica FA; Jacobsen SJ; King BF; Bostwick DG; Jacobson DJ; Girman CJ; Lieber MM
    J Urol; 1999 Mar; 161(3):831-4. PubMed ID: 10022695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.
    Fujimura T; Kume H; Nishimatsu H; Sugihara T; Nomiya A; Tsurumaki Y; Miyazaki H; Suzuki M; Fukuhara H; Enomoto Y; Homma Y
    BJU Int; 2012 May; 109(10):1512-6. PubMed ID: 21883834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and treatment of lower urinary tract symptoms in older men.
    Abrams P; Chapple C; Khoury S; Roehrborn C; de la Rosette J;
    J Urol; 2013 Jan; 189(1 Suppl):S93-S101. PubMed ID: 23234640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benign prostatic hyperplasia: clinical manifestations and evaluation.
    Santos Dias J
    Tech Vasc Interv Radiol; 2012 Dec; 15(4):265-9. PubMed ID: 23244722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence rates and risk factors for acute urinary retention: the health professionals followup study.
    Meigs JB; Barry MJ; Giovannucci E; Rimm EB; Stampfer MJ; Kawachi I
    J Urol; 1999 Aug; 162(2):376-82. PubMed ID: 10411042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are polymorphisms of the β(3)-adrenoceptor gene associated with an altered bladder function?
    Teitsma CA; de la Rosette JJ; Michel MC
    Neurourol Urodyn; 2013 Mar; 32(3):276-80. PubMed ID: 22972489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention.
    Nickel JC; Roehrborn CG; Castro-Santamaria R; Freedland SJ; Moreira DM
    J Urol; 2016 Nov; 196(5):1493-1498. PubMed ID: 27378134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of chromosomal locus 8q24 and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy.
    Meyer A; Schürmann P; Ghahremani M; Kocak E; Brinkhaus MJ; Bremer M; Karstens JH; Hagemann J; Machtens S; Dörk T
    Urol Oncol; 2009; 27(4):373-6. PubMed ID: 18625567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.
    Oh JJ; Byun SS; Lee SE; Hong SK; Jeong CW; Kim D; Kim HJ; Myung SC
    Gene; 2014 Jan; 533(1):86-93. PubMed ID: 24120391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.